H
Hadas Dvory-Sobol
Researcher at Queen Mary University of London
Publications - 48
Citations - 7299
Hadas Dvory-Sobol is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Sofosbuvir & Hepatitis C. The author has an hindex of 31, co-authored 42 publications receiving 6663 citations.
Papers
More filters
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam H. Afdhal,K. Rajender Reddy,David R. Nelson,Eric Lawitz,Stuart C. Gordon,Eugene R. Schiff,Ronald Nahass,Reem Ghalib,Norman Gitlin,Robert Herring,Jacob Lalezari,Ziad Younes,Paul J. Pockros,Adrian M. Di Bisceglie,Sanjeev Arora,G. Mani Subramanian,Yanni Zhu,Hadas Dvory-Sobol,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Mark S. Sulkowski,Paul Y. Kwo +24 more
TL;DR: Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologyic response to prior interferon-based treatment.
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
TL;DR: The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produced high rates of SVR12 in patients with advanced liver disease, including those with decompensated cirrhosis before and after liver transplantation.
Journal ArticleDOI
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
TL;DR: In this article, the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuvir, and ribavirin were used to treat chronic hepatitis C virus (HCV) infection in patients with advanced liver disease.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie,Curtis Cooper,Michael S. Saag,Kimberly A. Workowski,Peter Ruane,William J. Towner,Kristen M. Marks,Anne F Luetkemeyer,Rachel Baden,Rachel Baden,Paul E. Sax,E.J. Gane,Jorge Santana-Bagur,Luisa M. Stamm,Jenny C. Yang,Polina German,Hadas Dvory-Sobol,Liyun Ni,Phillip S. Pang,John G. McHutchison,Catherine A.M. Stedman,Javier O Morales-Ramirez,Norbert Bräu,Norbert Bräu,Dushyantha Jayaweera,Amy E. Colson,Pablo Tebas,David Wong,Douglas T. Dieterich,Mark S. Sulkowski +29 more
TL;DR: Ledipasvir and sofosbuvir as a single fixed-dose combination for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4.